
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Minimal change disease immunohistology
Introduction
Overview
Overview
A kidney biopsy is not routinely performed as soon as nephrotic syndrome is found during lab work-up. According to the National Kidney Foundation (NKF) Kidney Disease β Improve Global Outcomes (KDIGO) guidelines in 2012, an initial attempt using corticosteroids should be performed before a renal biopsy is performed. A renal biopsy of minimal change disease shows no or minimal abnormalities on light microscopy. Lipid-laden cells may be seen in proximal tubular epithelium. Renal biopsy is often unremarkable under immunofluorescence, with the exception of few cases that stain positively for IgM antibodies and C3.The hallmark of minimal change disease is absence of visible alterations on light microscopy and absence of effacement of foot processes by electron microscopy.
Immunohistology
Immunohistology
Light Microscopy
- A renal biopsy of minimal change disease shows no orΒ nearly normal with abnormalities on light microscopy.[1][2][3]
- Mesangial proliferation is seen on light microscopy.
- Lipid-laden cells may be seen in proximal tubular epithelium.
- Additional features of focal segmental glomerulosclerosis, such as mesangial prominence, interstitial fibrosis, and tubular atrophy, or glomerular tip lesions of focal segmental glomerulosclerosis, may be seen in patients who have complicated disease.[4]
- Those with acute renal injury may have histological features of focal flattening of the proximal tubular epithelium.[4]
Immunofluorescence
- Renal biopsy is often unremarkable under immunofluorescence, with the exception of few cases that stain positively for IgM antibodies and C3.[4]
References
References
- β Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH; et al. (2013). “KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis”. Am J Kidney Dis. 62 (3): 403β41. doi:10.1053/j.ajkd.2013.06.002. PMIDΒ 23871408.
- β Vivarelli, Marina; Massella, Laura; Ruggiero, Barbara; Emma, Francesco (2017). “Minimal Change Disease”. Clinical Journal of the American Society of Nephrology. 12 (2): 332β345. doi:10.2215/CJN.05000516. ISSNΒ 1555-9041.
- β Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). “Minimal Change Disease”. Clin J Am Soc Nephrol. 12 (2): 332β345. doi:10.2215/CJN.05000516. PMCΒ 5293332. PMIDΒ 27940460.
- β 4.0 4.1 4.2 D’Agati V (2003). “Pathologic classification of focal segmental glomerulosclerosis”. Semin Nephrol. 23 (2): 117β34. doi:10.1053/snep.2003.50012. PMIDΒ 12704572.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
